Cristiano Lingua¹*, Giuseppe Guida², Iuliana Badiu³, Andrea Antonelli² and Alberto Macchi⁴

¹ENT - M.D. Otorhinolaryngology and Head and Neck Surgery Department, ASO S. Croce and Carle Cuneo, Italy
²Immunologist and Allergist - M.D. SS Allergy and Respiratory Physiopathology, ASO S. Croce and Carle Cuneo, Italy
³Immunologist and Allergologist - M.D. SSdDU Immunology and Allergy, AO Mauriziano Order, Torino Italy
⁴ENT - M.D. ENT Department, Insubria University, ASST Sette Laghi, Varese, Italy

*Corresponding Author: Cristiano Lingua, ENT - M.D. Otorhinolaryngology and Head and Neck Surgery Department, ASO S. Croce and Carle Cuneo, Italy.

Received: June 23, 2021; Published: September 17, 2021

Abstract

  The epidemiological, clinical and phenotypic correlation between asthma and chronic rhinosinusitis (CRS), in particular with nasal polyps (CRSwNP), type 2 inflammatory respiratory pathologies, spread and addressed the research for a biomarker able to identify different phenotypes in asthma and CRSwNP at first, but also monitoring the effect of therapy, giving a right prognostic value in treatment. The nasal cytology has been proposed in this study as the biomarker: 31 patients (diagnosed as “severe or difficult-to-control asthma) were subjected to nasal cytology and were divided, on the basis of rhinocyte observation on the optic microscope in 5 categories: NARES (non-allergic rhinitis with eosinophilia), NARMA (NAR with mastocytosis), NARESMA, NARNE (neutrophils) and some patients had a normal cytology.

  In the study have been valued: CRSwNP, ASA hypersensibility atopia, mycotype specific IgE and staphylococcus toxins, total IgE, current and maximum eosinophilic count, oral corticosteroid treatment (OCS), TC score according with Lund-Mackay; it was evaluate the treatment with biological drugs (immunoclonal antibody).

  Patients with type 2 inflammatory respiratory pathology with asthma (severe or difficult-to-control) and CRSwNP associated the nasal cytology can provide a differentiation of patients in phenotype with eosinophilia (NARES), from the one with mastocytosis (NARMA). Blood eosinophilia, atopy, ongoing use of systemic treatment (OCS, biological drugs) do not appear to effect on the cytology panel).

Keywords: NARES (Non Allergic Rhinitis with Eosinophilia); Nasal Cytology; NARMA (NAR with mastocytosis); Nasal Polyposis; Asthma; Biomarker

References

1. William W Busse., et al. “Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation”. European Respiratory Journal (2021): 2003393.
2. Aiko I Klingler., et al. “Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps”. The Journal of Allergy and Clinical Immunology 4 (2021): 1306-1317.
3. Matteo Gelardi., et al. “Clinical-Cytological-Grading and phenotyping in patients with chronic rhinosinusitis with nasal polyps: the relevance in clinical practice”. Monaldi Archives for Chest Disease 90 (2020): 1277.
4. Heffler E., et al. “Nasal cytology: Methodology with application to clinical practice and research”. Clinical and Experimental Allergy 9 (2018): 1092-1106.
5. M Gelardi., et al. “NASAL cytology: practical aspects and clinical relevance”. Clinical and Experimental Allergy 46 (2016): 785-792.

Citation

Citation: Cristiano Lingua., et al. “Nasal Cytology as a Biomarker of Inflammatory Respiratory Pathology Type 2: Results of a Cross-Sectional Analysis". Acta Scientific Otolaryngology 3.10 (2021): 40-42.

Copyright

Copyright: © 2021 Cristiano Lingua., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.